HOUSTON / Apr 23, 2025 / Business Wire / U.S. Physical Therapy, Inc. (NYSE: USPH), a national operator of outpatient physical therapy clinics and provider of industrial injury prevention services, announced that it will report its financial results for the first quarter ended March 31, 2025, on Wednesday, May 7, 2025, after the stock market closes, with the conference call to follow the next morning, on Thursday, May 8, 2025.
Conference Call Date: | Thursday, May 8, 2025 |
|
| Time: | 10:30 am Eastern /9:30 am Central |
| Dial-In Number: | (800) 274-8461 Primary or |
|
| (203) 518-9814 Alternate |
| Conference ID: | USPHQ125 |
| (In order to join this conference call, | |
you will be required to provide the Conference ID listed above) | ||
To participate, please call in 15 minutes prior to start time. |
To listen to the live call, please go to www.usph.com and click on conference calls under the Investor Relations section. Please go to the website 15 minutes early to register, download and install any necessary audio software. If you are unable to listen live, a playback of the conference call can be accessed until August 6, 2025, at U.S. Physical Therapy’s website.
About U.S. Physical Therapy, Inc.
Founded in 1990, U.S. Physical Therapy, Inc. owns and/or manages 773 outpatient physical therapy clinics in 44 states. USPH clinics provide preventative and post-operative care for a variety of orthopedic-related disorders and sports-related injuries, treatment for neurologically-related injuries and rehabilitation of injured workers. USPH also has an industrial injury prevention business which provides onsite services for clients’ employees including injury prevention and rehabilitation, performance optimization, post-offer employment testing, functional capacity evaluations, and ergonomic assessments.
More information about U.S. Physical Therapy, Inc. is available at www.usph.com. The information included on that website is not incorporated into this press release.
Last Trade: | US$78.20 |
Daily Change: | -0.83 -1.05 |
Daily Volume: | 205,144 |
Market Cap: | US$1.180B |
April 30, 2025 March 03, 2025 February 26, 2025 December 02, 2024 |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load